Physician profile
James Hahn
NPI 1982993697
$907.06
in general payments reported to CMS, 2019-2025
27 companies · $210 in 2025
The $210 reported for 2025 was more than what 75% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.15 · 2020: $11.25 · 2021: $166 · 2022: $215 · 2023: $134 · 2024: $123 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $209.23 | 2020-2024 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $61.91 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $54.59 | 2022-2024 | Vaxelis, Gardasil 9, Rotateq |
| Cranial Technologies, INC | $52.41 | 2022-2024 | Doc Band |
| Collegium Pharmaceutical, INC. | $43.68 | 2025 | Jornay Pm |
| Abbott Laboratories | $41.31 | 2025 | Freestyle Libre 3 |
| Abbvie INC. | $39.02 | 2022 | |
| Tandem Diabetes Care, INC. | $35.95 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $33.72 | 2024-2025 | |
| Abiomed | $30.79 | 2025 | |
| Sanofi Pasteur INC. | $29.23 | 2021-2023 | |
| Seqirus USA INC | $23.45 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $23.32 | 2019 | |
| Medtronic, INC. | $22.40 | 2025 | Minimed 780g |
| Esperion Therapeutics, INC. | $20.46 | 2024 | Nexletol |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $20.28 | 2023 | Jornay Pm |
| Exact Sciences Corporation | $19.33 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.32 | 2023 | |
| Antares Pharma, INC. | $16.51 | 2024 | Xyosted |
| Alfasigma USA, INC. | $16.01 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.00 | 2022 | |
| Amgen INC. | $14.77 | 2022 | |
| Genentech USA, INC. | $13.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.80 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $13.38 | 2024 | Crysvita |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.36 | 2022 | |
| Pfizer INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.